ALT Team hashtag#KOODAC has published its first paper in Cell Press, tackling a long-standing question in solid tumours: how does MYC help cancers stay “invisible” to the immune system? In our new Q&A, KOODAC co-Team Lead Martin Eilers The Julius Maximilians University of Würzburg and first authors Leonie Uhl, Amel Aziba and Sinah Löbbert share the story behind the work, from the initial hypothesis to a new mechanistic model showing how MYC suppresses immune detection. The findings uncover a previously unrecognised role for MYC in immune evasion, opening new possibilities to target its oncogenic function while preserving essential physiological roles, with important implications for immunotherapy in solid tumours, including childhood cancers. A brilliant example of KOODAC’s cross-disciplinary model in action, the study also draws on structural biology expertise from Seychelle M. Vos (MIT), helping create tractable platforms to support downstream drug discovery.